B+
Bull case
25%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-05-07 · RankAlpha Sentiment Codex
RNA
Atrium TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive case is that Atrium launched with about $270 million in cash, a stated runway through clinical proof-of-concept, two lead cardiomyopathy assets, and ongoing collaboration optionality including up to $1.5 billion of potential R&D milestones from existing BMS and Lilly collaborations [#PR-2026-02-27] [#IR-2026-02].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +30.1.
What can break
Collaboration economics are milestone-based and contingent; the April payment is positive, but future BMS or Lilly value realization is not assured [#PR-2026-04-23] [#IR-2026-02].
Momentum
83
Value
59
Sentiment
87
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.00 · Bull $20.00 · Bear $7.00Analysis 2026-05-07; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $25.00
Why
Momentum83 · Δ7d -4.9
Value59 · Δ7d 0.0
Sentiment87 · Δ7d +30.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +30.1.
Contradictions & invalidation
- • Collaboration economics are milestone-based and contingent; the April payment is positive, but future BMS or Lilly value realization is not assured [#PR-2026-04-23] [#IR-2026-02].
- • Even with roughly $270 million at launch, delays to ATR 1072 or ATR 1086 could shorten the runway to proof-of-concept and reopen financing risk [#PR-2026-02-27] [#IR-2026-02].
- • The bear case is that RNA is still a newly spun, low-coverage, preclinical biotech with no clinical data yet for its lead assets, sparse external validation beyond the recent collaboration milestone, and high dependency on hitting IND and early-trial execution gates before the market can justify a stronger rerating.
Catalyst clock
2026-04-23
$15 million Bristol Myers Squibb milestone supports platform validation and cash buffer
Lead driver: Sentiment · See AI snapshot
Momentum
83
9% active weight
Current posture
7d trendSoftening
Δ7d
-4.9
Δ21d
+72.2
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Sentiment
87
62% active weight
Current posture
7d trendImproving
Δ7d
+30.1
Δ21d
+18.4
Why this grade
Composite grade A. Momentum 82.9 / Value 58.8 / Sentiment 86.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-07. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-05-07 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-05-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$221.69M
Beta
0.93
Shares Out
17.11M
P/E (TTM) · Derived
-4.5
P/S (TTM)
520.38
P/FCF (TTM) · Derived
-2.86
Rev YoY
-21.9%
EPS YoY
+56.7%
Gross Margin
-
Op Margin
-2934.9%
Net Debt
$3.67M
Current Ratio
8.73
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data